Perpetual Ltd Trims Stake in Autolus Therapeutics plc (NASDAQ:AUTL)

Perpetual Ltd cut its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 33.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,599,252 shares of the company's stock after selling 801,160 shares during the period. Perpetual Ltd owned about 0.60% of Autolus Therapeutics worth $5,805,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sierra Summit Advisors LLC purchased a new stake in Autolus Therapeutics during the 4th quarter worth about $275,000. Perceptive Advisors LLC acquired a new position in Autolus Therapeutics in the 4th quarter valued at about $11,793,000. China Universal Asset Management Co. Ltd. increased its position in Autolus Therapeutics by 66.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 27,034 shares of the company's stock valued at $172,000 after acquiring an additional 10,771 shares during the period. Privium Fund Management B.V. increased its position in Autolus Therapeutics by 43.2% in the 1st quarter. Privium Fund Management B.V. now owns 50,058 shares of the company's stock valued at $319,000 after acquiring an additional 15,091 shares during the period. Finally, BNP Paribas Financial Markets increased its position in Autolus Therapeutics by 2,603.8% in the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company's stock valued at $736,000 after acquiring an additional 111,131 shares during the period. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Price Performance

Shares of NASDAQ:AUTL traded up $0.03 during trading on Friday, hitting $4.14. 1,101,853 shares of the stock were exchanged, compared to its average volume of 1,360,001. The company has a fifty day moving average price of $3.88 and a two-hundred day moving average price of $4.19. The company has a market cap of $1.10 billion, a PE ratio of -3.57 and a beta of 2.04. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09. Autolus Therapeutics plc has a 12-month low of $2.21 and a 12-month high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, analysts forecast that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a report on Monday, June 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $8.70.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.